Glutamate is a major neurotransmitter in the brain, and its role in drug addiction remains a hot topic in animal research aimed to unravel neurochemical mechanisms for addictive properties of drugs of abuse. This lab has long been supported for studying roles of metabotropic glutamate receptors (mGluRs). In the last period of grant, we have identified that group I mGluRs (mGluR1 and 5 subtypes) that are densely expressed in the striatum are key regulators of drug action. Specifically, activation of group I mGluRs is required for acutely- administered psychostimulant amphetamine (AMPH) to enhance endogenous dynorphin activity in rat striatal neurons, a critical response that was thought to homeostatically inhibit drug effects. One form of long-lasting behavioral plasticity, behavioral sensitization to repeated AMPH injections in rats, is a widely-used animal model because it mimics the intensification of drug craving in human addicts. Interestingly, we have recently found that repeated AMPH administration markedly reduced group I mGluR mRNAs and proteins in the striatum. This raises an innovative question as to whether repeated AMPH injections could progressively downregulate the group I mGluR expression and thus function in activating inhibitory dynorphin and thereby induce behavioral sensitization. In this continuation proposal, a series of experiments was therefore proposed to evaluate an overarching hypothesis that the downregulation of group I mGluRs contributes to behavioral sensitization to repeated AMPH administration. Using multidisciplinary approaches, this hypothesis will be tested in rodents in vivo in three AIMs. In these AIMs, we will (1) explore and characterize the reduction of mGluR1 and mGluR5 protein expression in the striatum in response to repeated AMPH administration, and elucidate cellular mechanisms for such reduction, (2) define functional consequences of reduced mGluR1/5 expression in terms of mGluR1/5-mediated functions by examining effects of repeated AMPH administration on the prime mGluR1/5-mediated cellular and genomic responses in striatal neurons, including phosphoinositide hydrolysis, intracellular Ca2+ release, MAPK/ERK activation, transcription factor (CREB) phosphorylation, and dynorphin gene expression, and (3) define functional roles of the downregulated mGluR1/5 in behavioral sensitization by examining behavioral sensitization to repeated AMPH administration in rats in which reduced mGluR1/5 protein expression is reversed or restored by viral-mediated transgene expression or by proteasome inhibitors, or in rats in which mGluR1/5 proteins are experimentally reduced by an antisense or genetic approach. Results achieved here from molecule to behavior will provide evidence for a new molecular mechanism underlying drug action, and will ultimately contribute to the development of novel pharmacotherapies, by targeting the group I mGluRs, for the treatment of various mental illnesses stemmed from substance abuse.

Public Health Relevance

Substance abuse and addiction is among major social, economic, and health problems. This application is proposed to discover brain mechanisms critical for the addictive properties of drugs of abuse. The findings through this research project will promote the development of novel pharmacotherapies for the treatment of various mental illnesses stemmed from substance abuse.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA010355-17
Application #
8212294
Study Section
Molecular Neuropharmacology and Signaling Study Section (MNPS)
Program Officer
Wu, Da-Yu
Project Start
1997-09-16
Project End
2013-09-14
Budget Start
2012-01-01
Budget End
2013-09-14
Support Year
17
Fiscal Year
2012
Total Cost
$321,941
Indirect Cost
$105,873
Name
University of Missouri Kansas City
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
010989619
City
Kansas City
State
MO
Country
United States
Zip Code
64110
Mao, Li-Min; Faris, Hunter J; Wang, John Q (2018) Muscarinic Acetylcholine Receptors Inhibit Fyn Activity in the Rat Striatum In Vivo. J Mol Neurosci 64:523-532
Mao, Li-Min; He, Nan; Jin, Dao-Zhong et al. (2018) Regulation of Phosphorylation of AMPA Glutamate Receptors by Muscarinic M4 Receptors in the Striatum In vivo. Neuroscience 375:84-93
Mao, Li-Min; Wang, John Q (2018) Alterations in mGlu5 receptor expression and function in the striatum in a rat depression model. J Neurochem 145:287-298
He, Nan; Mao, Li-Min; Sturich, Adrian W et al. (2018) Inhibition of basal and amphetamine-stimulated extracellular signal-regulated kinase (ERK) phosphorylation in the rat forebrain by muscarinic acetylcholine M4 receptors. Brain Res 1688:103-112
Xue, Bing; Mao, Li-Min; Jin, Dao-Zhong et al. (2018) Pharmacological modulation of AMPA receptor phosphorylation by dopamine and muscarinic receptor agents in the rat medial prefrontal cortex. Eur J Pharmacol 820:45-52
Jin, Dao-Zhong; Mao, Li-Min; Wang, John Q (2018) The Role of Extracellular Signal-Regulated Kinases (ERK) in the Regulation of mGlu5 Receptors in Neurons. J Mol Neurosci 66:629-638
Mao, Li-Min; Wang, Henry H; Wang, John Q (2017) Antagonism of Muscarinic Acetylcholine Receptors Alters Synaptic ERK Phosphorylation in the Rat Forebrain. Neurochem Res 42:1202-1210
Yang, Ju Hwan; Mao, Li-Min; Choe, Eun Sang et al. (2017) Synaptic ERK2 Phosphorylates and Regulates Metabotropic Glutamate Receptor 1 In Vitro and in Neurons. Mol Neurobiol 54:7156-7170
Jin, Dao-Zhong; Mao, Li-Min; Wang, John Q (2017) An Essential Role of Fyn in the Modulation of Metabotropic Glutamate Receptor 1 in Neurons. eNeuro 4:
Xue, Bing; Chen, Elton C; He, Nan et al. (2017) Integrated regulation of AMPA glutamate receptor phosphorylation in the striatum by dopamine and acetylcholine. Neuropharmacology 112:57-65

Showing the most recent 10 out of 73 publications